logo
logo
Health Catalyst, Inc.

Health Catalyst, Inc.

NASDAQ•HCAT
CEO: Mr. Daniel D. Burton
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2019-07-25
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
連絡先情報
10897 South River Front Parkway, Suite 300, South Jordan, UT, 84095, United States
801-708-6800
www.healthcatalyst.com
時価総額
$145.71M
PER (TTM)
-1.3
53
配当利回り
--
52週高値
$5.68
52週安値
$2.02
52週レンジ
1%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$76.32M-0.04%
直近4四半期の推移

EPS

-$0.32+33.33%
直近4四半期の推移

フリーCF

-$5.27M-393.98%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Total Revenue Increased 4% Nine months total revenue reached $236.5M, up 4% from $227.0M, driven by new and existing client growth.
Adjusted EBITDA Significantly Improved Nine months Adjusted EBITDA grew to $27.6M, a 51% increase over $18.2M last year, showing operational leverage.
Technology Revenue Grew 9% Technology revenue for nine months was $156.4M, marking 9% growth, while Professional Services revenue declined 4%.
Goodwill Impairment Recorded Recorded $28.8M non-cash goodwill impairment charge as of June 30, 2025, primarily impacting the Technology reporting unit.

リスク要因

Macroeconomic Pressures Persist High inflation, interest rates, and Medicaid funding uncertainty negatively affect client budgets and elongate sales cycles.
Goodwill Impairment Triggered Interim goodwill test showed reporting units below carrying values, resulting in $28.8M impairment charge for nine months 2025.
Ignite Migration Pressures Margins DOS client migration to Ignite increases near-term technology cost of revenue, potentially causing near-term Adjusted Technology Gross Margin decline.
Client Contract Renewal Risk Significant revenue relies on renewals; clients may reduce spend or fail to renew, materially impacting future financial results.

見通し

Focus on Ignite Migration Continuing DOS client migration to Ignite, expecting two-thirds complete by end of 2025, prioritizing client flexibility.
Executing Cost Optimization Plan Authorized August 2025 Restructuring Plan to reduce headcount and optimize cost structure, expecting $0.5M additional costs Q4 2025.
Future Bookings Mix Shift Anticipating higher proportion of gross bookings from existing client base through upsells rather than solely new Platform Clients.
Sufficient Near-Term Liquidity Existing cash, cash equivalents, and marketable securities of $91.5M are sufficient for working capital needs over next 12 months.

同業比較

売上高 (TTM)

Atlantic International Corp.ATLN
$445.38M
+3.8%
Health Catalyst, Inc.HCAT
$316.06M
+4.6%
Neuronetics, Inc.STIM
$129.87M
+78.6%

粗利益率 (最新四半期)

Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp
Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp
Invivyd, Inc.IVVD
91.7%
+0.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ACRS$395.46M-3.2-102.8%1.3%
ENTA$328.05M-5.7-78.6%17.3%
OBIO$235.46M-2.1-320.1%1.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.4%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月25日
|
EPS:$0.10
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月10日|
    売上高: $76.32M-0.0%
    |
    EPS: $-0.32+33.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $80.72M+6.3%
    |
    EPS: $-0.59+156.5%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $79.41M+6.3%
    |
    EPS: $-0.35+0.0%
    予想を下回る

  • Form 10-K/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年4月30日|
    売上高: $306.58M+3.6%
    |
    EPS: $-1.15+45.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月26日|修正版データを参照

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $76.35M+3.5%
    |
    EPS: $-0.24-38.5%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $75.90M+3.7%
    |
    EPS: $-0.23-60.3%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $74.72M+1.2%
    |
    EPS: $-0.35-41.7%
    予想を下回る